B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 + tumor-infiltrating lymphocytes-Reference-Cited by-同舟云学术

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 + tumor-infiltrating lymphocytes

Published:2021-01-15 Issue:3 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

You Gihoon¹^ORCID,Lee Yangsoon²^ORCID,Kang Yeon-Woo¹^ORCID,Park Han Wook¹^ORCID,Park Kyeongsu²^ORCID,Kim Hyekang¹^ORCID,Kim Young-Min¹^ORCID,Kim Sora¹,Kim Ji-Hae³^ORCID,Moon Dain¹^ORCID,Chung Hyejin²,Son Wonjun²,Jung Ui-jung²^ORCID,Park Eunyoung²,Lee Shinai²,Son Yong-Gyu²,Eom Jaehyun²,Won Jonghwa²,Park Yunji¹^ORCID,Jung Jaeho²^ORCID,Lee Seung-Woo¹³^ORCID

Affiliation:

1. Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea.

2. ABL Bio Inc., Seongnam, Republic of Korea.

3. Department of Life Sciences, POSTECH, Pohang, Republic of Korea.

Abstract

Tumor-targeted T cell costimulatory antibody augments antitumor immunity by enhancing tumor-killing T cells within the tumor.

Funder

Ministry of Education

ABL Bio, Inc.

Dong-A ST Co., Ltd.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference56 articles.

1. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials

2. Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies

3. Cancer immunotherapy using checkpoint blockade

4. Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand

5. Tumor Necrosis Factor/Tumor Necrosis Factor Receptor Family Members That Positively Regulate Immunity

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer;Frontiers in Immunology;2024-01-22

2. 4-1BB immunotherapy: advances and hurdles;Experimental & Molecular Medicine;2024-01-04

3. The anti-B7-H3 blocking antibody MJ18 does not recognize B7-H3 in murine tumor models;2023-11-17

4. Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade;Frontiers in Immunology;2023-10-31

5. 4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T;Cancer Biotherapy and Radiopharmaceuticals;2023-09-01